| Assessment Status |
Awaiting HTA submission from Applicant |
| HTA ID |
22020 |
| Drug |
Abemaciclib |
| Brand |
Verzenios® |
| Indication |
in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence. |
| Rapid review commissioned |
11/04/2022 |
| Rapid review completed |
06/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/05/2022 |
| Pre-submission consultation with Applicant |
26/07/2022 |
